Caligan Partners’s Tango Therapeutics TNGX Stock Holding History
Bought
Maintained
Sold
Other funds holding TNGX
SL
Caligan Partners's TNGX Position: Q3 2026 in Review
Caligan Partners increased its Tango Therapeutics (TNGX) stake by 0.05% in Q3 2026, buying an estimated $29.8K and bringing the position to 2,501,246 shares worth $62.4M. The position accounts for 3.82% of the portfolio, ranked #6.
Caligan Partners first reported a position in TNGX in Q4 2025 and has held it in 4 quarters since. The position peaked at $78.2M in Q2 2026. 257 funds tracked by Wall St. Rank hold TNGX as of Q3 2026.
- Caligan Partners held 2,501,246 shares of Tango Therapeutics worth $62.4M as of Q3 2026.
- Caligan Partners bought 1,143 Tango Therapeutics shares in Q3 2026, an estimated $29.8K.
- Tango Therapeutics made up 3.82% of Caligan Partners's portfolio in Q3 2026, its #6 holding.
- Caligan Partners first reported a position in Tango Therapeutics in Q4 2025 and has held it in 4 quarters since.
- Caligan Partners's Tango Therapeutics position peaked at $78.2M in Q2 2026.
- 257 funds tracked by Wall St. Rank held Tango Therapeutics as of Q3 2026.
Based on Caligan Partners's 13F filing for Q3 2026, filed 16 Nov 2026.